Search

Vericiguat

[L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure.

Capmatinib

Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,[L13380] for the treatment of NSCLC in patients whose tumors have

Upadacitinib

[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration.[L10896].

Citronella oil

Cinnamon leaf oil

Biotin

A water-soluble, enzyme co-factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk.

Mineral oil

Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that ar...

Pemigatinib

Pemigatinib is marketed under the brand name Pemazyre, and it is available as oral tablets.[L13050]

Fidanacogene elaparvovec

[A262929] On January 3, 2024, fidanacogene elaparvovec was approved by Health Canada under the brand name BEQVEZ for the treatment of adults with moderately severe to severe hemophilia B (congenital

Fruquintinib

[A262097] On November 8th, 2023, fruquintinib was approved by the FDA under the brand name Fruzaqla for the treatment of adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine